Fennec Pharmaceuticals Stock (NASDAQ:FENC)
Previous Close
$8.70
52W Range
$5.65 - $10.45
50D Avg
$7.75
200D Avg
$8.03
Market Cap
$252.93M
Avg Vol (3M)
$263.28K
Beta
1.08
Div Yield
-
FENC Company Profile
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated in Research Triangle Park, North Carolina.
FENC Performance
Peer Comparison
| Ticker | Company |
|---|---|
| AARD | Aardvark Therapeutics, Inc. Common Stock |
| BDTX | Black Diamond Therapeutics, Inc. |
| ENTA | Enanta Pharmaceuticals, Inc. |
| RNAC | Cartesian Therapeutics, Inc. |
| AVTX | Avalo Therapeutics, Inc. |
| PRLD | Prelude Therapeutics Incorporated |
| OBIO | Orchestra BioMed Holdings, Inc. |
| EPRX | Eupraxia Pharmaceuticals Inc. |
| NAUT | Nautilus Biotechnology, Inc. |
| CRBU | Caribou Biosciences, Inc. |